In this article, we will give you an overview of Humira biosimilars, including their benefits, availability, prices, and how they compare to Humira. We will also answer some frequently asked questions about Humira biosimilars and provide some tips on how to switch from Humira to a biosimilar safely and smoothly. Humira is a brand-name medication … Read more
While several biosimilars of AbbVie’s top-selling drug, Humira, are already available in the US market, only one, Boehringer Ingelheim’s Cyltezo, has achieved the coveted interchangeable status. This designation allows Cyltezo to be switched for the original Humira without the need for prescriber intervention. Samsung Bioepis and its marketing partner, Organon, now have the clinical data … Read more
Source – Novartis July 20, 2023, Sandoz, a renowned global leader in generic and biosimilar medicines, has disclosed a substantial investment of around USD 90 million to establish the dedicated Sandoz Biopharma Development Center at its site in Ljubljana, Slovenia. By 2026, this development center is set to become one of Sandoz’s key locations for … Read more
Pharmacy benefits manager (PBM) RxPreferred has unveiled its plan to provide the Humira biosimilar Yusimry through Mark Cuban Cost Plus Drugs, an online pharmacy launched by celebrity investor Mark Cuban in 2022. Commencing in July 2023, RxPreferred aims to offer Yusimry to its members for a price of $569.27, in addition to dispensing and shipping … Read more
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection in the United States. They introduced the citrate-free high-concentration formulation (HCF) of Hyrimoz, which will be accessible from that date onwards. Hyrimoz HCF, with a concentration of 100 mg/mL, has received approval for the treatment … Read more
Source – UCB On 27 June 2023, UCB faced regulatory challenges in the United States for the second consecutive year, including a delay in the FDA’s review of its application for the plaque psoriasis candidate bimekizumab. However, UCB received positive news from the FDA, granting approval for Rystiggo (rozanolixizumab-noli) to treat the rare autoimmune condition … Read more
Source – Eli Lilly On June 20, 2023 a formal deal for Lilly to purchase DICE was announced by Eli Lilly & Company and DICE Therapeutics. Eli Lilly has agreed to pay Dice Therapeutics and its platform for the discovery and development of oral, small molecule treatments for immunological illnesses $2.4 billion. DICE is a … Read more
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar medicine that imitates Johnson & Johnson’s best-selling medication Stelara without facing any legal challenges for patent infringement. Alvotech and Teva have been given a license by J&J to market its envisioned Stelara Biosimilar, AVT04, in … Read more
The FDA has granted acceptance to Merck’s application for the popular drug Keytruda, in combination with standard-of-care chemotherapy (gemcitabine plus cisplatin), for the treatment of biliary tract cancer (BTC). The application is supported by data from the phase 3 KEYNOTE-966 trial involving 1,069 patients, which demonstrated that Keytruda significantly improved survival compared to chemotherapy alone. … Read more
pharmtales
Latest Pharma News & Insights
